Effectiveness
How well a drug works in real-world clinical practice, where patient populations are more diverse and adherence less controlled than in trials. Effectiveness may be lower than efficacy because real-world conditions differ from the carefully managed clinical trial environment.
Technical Context
Effectiveness-efficacy gaps arise from: variable adherence (missed doses, early discontinuation — GLP-1 RA 12-month persistence rates range from 30-70% in real-world data vs >90% in trials), broader patient populations (trial exclusion criteria screen out complicating comorbidities), less intensive monitoring (trial visits every 4-12 weeks include motivational support that routine care doesn't match), and concomitant medication changes (real-world polypharmacy may differ from controlled trial protocols). Pragmatic trials (designed to mirror real-world practice) bridge the efficacy-effectiveness gap. Real-world effectiveness studies of GLP-1 RAs consistently show lower HbA1c and weight reduction than trials, primarily driven by adherence — patients who persist on therapy achieve outcomes close to trial efficacy.